Other equities research analysts have also issued research reports about the stock. Liberum Capital set a CHF 279 price objective on shares of Roche and gave the company a buy rating in a research note on Wednesday, November 22nd. Baader Bank set a CHF 256 price objective on shares of Roche and gave the company a buy rating in a research note on Tuesday, November 21st. JPMorgan Chase & Co. reiterated a buy rating on shares of Roche in a research note on Friday, November 17th. Goldman Sachs Group set a CHF 325 price objective on shares of Roche and gave the company a buy rating in a research note on Monday, November 20th. Finally, Sanford C. Bernstein set a CHF 262 price objective on shares of Roche and gave the company a buy rating in a research note on Friday, December 1st. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus price target of CHF 256.05.
Shares of Roche (VTX:ROG) opened at CHF 222.80 on Monday. The company has a market cap of $192,870.00 and a PE ratio of 22.19. Roche has a one year low of CHF 214.30 and a one year high of CHF 273.
COPYRIGHT VIOLATION NOTICE: This article was originally published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3225275/roche-rog-given-a-chf-290-price-target-at-jefferies-group.html.
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.